You are here: Industry Insights > Market News > Advent to Acquire Sanofi's Generics Biz in Europe

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Probiotic strains and blends

NERVONIC ACID

百靈威J&K 降冰片烯 175425

百靈威J&K 三(3-羥基丙基)膦

百靈威J&K 三正辛基氧化膦 318216

百靈威J&K 三(2-羧乙基)膦鹽酸鹽 312334

Advent to Acquire Sanofi's Generics Biz in Europe

contractpharmaJuly 03, 2018

Tag: Advent , Acquire Sanofi , Generics Biz

Favorites

Sanofi and Advent International have finished negotiations for the acquisition of Zentiva, Sanofi's European generics business, by Advent. The companies have signed a Share Purchase Agreement worth €1.9 billion. The companies announced that they had entered into exclusive talks on April 17, 2018.

The signing of this Share Purchase Agreement marks a critical step on the way to the closing of the deal and the transfer of the Zentiva business to Advent, that is anticipated during the course of the fourth quarter of 2018.

The transaction remains subject to the approval of the competent regulatory authorities.

Previous:Adents Launches Verification Router Service Title

Next:Kymab, Roche Partner to Evaluate KY1044

Alzheimer’s Disease: Charting the Course from Plaques to Promise

Muhammad Farhan KhalidMay 28, 2025

New Tools，New Hope，New Frontier

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

PharmaSourcesMay 16, 2025

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

PR NewswireMay 12, 2025

Advent to Acquire Sanofi's Generics Biz in Europe | Pharmasources.com

Illuccix China Phase 3 Study Completes Enrolment

PR NewswireMay 13, 2025

Telix Pharmaceuticals Limited announces that the pivotal Phase 3 registration study of TLX591-CDx for prostate cancer imaging in Chinese patients has completed patient enrolment.